Rule 11 Medication Inquiries: “Clearheadedness” Suffices Absent Red Flags; Prejudice Required on Plain-Error Review

I. Introduction

In United States v. Boria (2d Cir. Feb. 4, 2026), the Second Circuit addressed how far a district court must go under Federal Rule of Criminal Procedure 11 when a defendant discloses having taken prescribed medications shortly before a guilty plea. The defendant-appellant, Steve Boria, pleaded guilty in the Southern District of New York to narcotics conspiracy and firearm-related conduct connected to an alleged gang enterprise. He later argued that his plea was invalid because the plea court did not sufficiently inquire into the side effects and potential cognitive impacts of medications he took for sleeping problems and bipolar disorder the night before the plea.

The key issues were: (1) whether the plea court complied with Rule 11’s requirement to ensure a knowing and voluntary plea when medication use is disclosed, and (2) whether, on plain-error review, Boria could obtain reversal without showing prejudice by characterizing the alleged Rule 11 lapse as “structural error.”

II. Summary of the Opinion

The Second Circuit affirmed. It held that the plea court did not violate Rule 11 where it followed up on the defendant’s disclosure of medication use by asking whether he was “clearheaded” and understood what was happening in court, and where the record showed no “red flags” suggesting impairment. The panel further held that, even assuming error, Boria failed to satisfy the prejudice requirement for plain-error relief because he did not show a reasonable probability that he would not have pleaded guilty but for the alleged error. Judge Lohier concurred in part and in the judgment, concluding that the absence of prejudice alone resolved the appeal.

III. Analysis

A. Precedents Cited

  • United States v. Rossillo, 853 F.2d 1062 (2d Cir. 1988): The foundational Second Circuit Rule 11 case for pleas entered under potential influence of drugs/medication. It requires the court, when there is “any indication” of medication or intoxicants, to “explore on the record” the defendant’s ability to understand the nature and consequences of pleading guilty. Boria treats Rossillo as setting the governing standard, but emphasizes that the inquiry’s adequacy depends on whether anything in the record signals actual impairment.
  • United States v. Yang Chia Tien, 720 F.3d 464 (2d Cir. 2013): A key comparator where the defendant said he understood only “fifty percent” of what was happening and answered “yeah” when asked whether medications affected his ability to hear or think. The Second Circuit vacated because the exchange created obvious “red flags” and the district court did not adequately investigate whether medication interfered with comprehension. In Boria, the court narrows Yang Chia Tien to its facts: the duty to go further is triggered when the record suggests impairment or confusion.
  • Hanson v. Phillips, 442 F.3d 789 (2d Cir. 2006): Reinforces that voluntariness is assessed under the “totality of the relevant circumstances.” Boria uses Hanson to frame the inquiry as holistic—what the defendant said, how he behaved, and whether anything suggested he did not understand the plea.
  • United States v. Savinon-Acosta, 232 F.3d 265 (1st Cir. 2000): Quoted for the “critical question” in medication cases—whether drugs that could impair ability actually did so “on this occasion.” Boria adopts this functional approach rather than requiring a categorical checklist of medication side effects.
  • United States v. Nicholson, 676 F.3d 376 (4th Cir. 2012); United States v. Hardimon, 700 F.3d 940 (7th Cir. 2012); United States v. Dalman, 994 F.2d 537 (8th Cir. 1993): Sister-circuit authorities cited to support affirmance where courts asked comprehension-focused questions (e.g., whether the defendant could think clearly, understood what was happening “right now,” and was sober) and where the defendant’s demeanor and answers showed lucidity.
  • United States v. Re, 682 F. App’x 33 (2d Cir. 2017); United States v. Brooks, 756 F. App’x 52 (2d Cir. 2018): Second Circuit summary orders reinforcing that asking about medication and whether it affects understanding can suffice, particularly when counsel raises no competency objection and the plea colloquy is coherent.
  • United States v. Adams, 768 F.3d 219 (2d Cir. 2014): Supplies the Second Circuit’s four-part plain-error framework and illustrates that failure to show a reasonable probability of a different plea decision defeats Rule 11 plain-error claims.
  • United States v. Dominguez Benitez, 542 U.S. 74 (2004): The Supreme Court rule that a defendant challenging a guilty plea on plain-error review must show “a reasonable probability” that, but for the Rule 11 error, he would not have pleaded guilty. Boria relies on Dominguez Benitez to reject relief absent prejudice.
  • United States v. Marcus, 560 U.S. 258 (2010): Cited to define “structural errors” as a “very limited class” affecting the framework of the proceedings. Boria uses Marcus (and Dominguez Benitez’s footnote) to reject the argument that the alleged omission was structural.

B. Legal Reasoning

  1. Rule 11’s goal is voluntariness and understanding, not a pharmacology inventory. The opinion treats Rule 11 as demanding an on-the-record determination that the plea is knowing and voluntary. When medication use is disclosed, the court must “explore on the record” the defendant’s ability to understand the consequences of pleading guilty (from United States v. Rossillo), but the court in Boria emphasizes the inquiry’s purpose: detecting impairment that undermines comprehension.
  2. “Red flags” drive how deep the inquiry must go. The panel distinguishes cases requiring reversal (notably United States v. Rossillo and United States v. Yang Chia Tien) on the ground that those records contained ambiguity, confusion, or admissions of limited understanding. In Boria’s case, the plea judge:
    • identified the medications’ purpose (sleeping problems and bipolar disorder),
    • confirmed timing (taken the night before),
    • asked whether Boria was “clearheaded” and understood the proceedings, and
    • invited counsel and the Government to object to competency (none did).
    The panel then looked to the rest of the colloquy, where Boria answered cogently, and found no indication of impairment.
  3. Side effects questioning is required only to the extent it bears on comprehension. Boria argued the court had to ask specifically about “side effects,” relying on language in United States v. Yang Chia Tien. The panel’s clarification is practical: Rule 11 requires questions sufficient to determine whether medication interferes with understanding; asking whether the defendant is clearheaded and understands what is happening directly addresses that concern. Absent contradictory responses or other indicia of confusion, the court need not go further.
  4. Plain-error review: prejudice is mandatory; “structural error” is rejected. Applying United States v. Adams and United States v. Dominguez Benitez, the court holds that even if there were a Rule 11 defect, reversal would still require a reasonable probability that the defendant would not have pleaded guilty. Boria’s attempt to avoid that requirement by labeling the omission “structural” fails under United States v. Marcus and Dominguez Benitez’s guidance that Rule 11 omissions are not “colorably structural” “without more.”
  5. Judge Lohier’s concurrence narrows the decision’s necessary reach. Judge Lohier concurred only in the prejudice holding, signaling that appellate courts can (and sometimes should) resolve medication-and-Rule-11 disputes on the Dominguez Benitez prejudice prong alone, without opining on the precise contours of the Rule 11 inquiry.

C. Impact

1. For plea colloquies in the Second Circuit.
Boria strengthens a pragmatic, record-based approach: when medication use is disclosed, the court should ask targeted questions that test present comprehension (e.g., “clearheaded,” “do you understand what is happening”), and then look for objective “red flags” in demeanor and answers. It does not require an automatic, detailed inquiry into a medication’s name, dosage, or every possible side effect so long as the record otherwise supports lucidity.

2. For defendants raising Rule 11 medication challenges on appeal.
The decision underscores two hurdles: (i) absent signs of confusion, courts will likely find Rule 11 satisfied if the judge asked comprehension-focused questions, and (ii) on plain-error review, defendants must produce a concrete showing that the alleged deficiency mattered to the plea decision—generalized speculation about side effects will usually be insufficient.

3. For litigation strategy (trial and appellate).
Defense counsel who believe medication could impair comprehension should build a record at the plea hearing—request a brief recess, confer with the client, ask the court to inquire further, or raise competency concerns if warranted. On appeal, Boria signals that the absence of such contemporaneous “red flags” will weigh heavily against relief.

IV. Complex Concepts Simplified

  • Rule 11 (plea colloquy): The set of procedures requiring the judge to ensure a guilty plea is voluntary and that the defendant understands the rights being waived, the charges, and the consequences.
  • Voluntary and knowing plea: A plea is valid only if the defendant is acting by choice (not coerced) and with a real understanding of what the plea means and what rights are being given up.
  • Plain-error review: When a defendant did not object in the trial court, the appellate court applies a demanding four-part test; the defendant must show not only a clear legal mistake, but also that it likely affected the outcome and seriously harmed the judicial process.
  • Prejudice (in this context): The defendant must show a reasonable probability that he would have rejected the plea and gone to trial if the Rule 11 error had not occurred.
  • Structural error: A rare category of fundamental defects that automatically require reversal because they undermine the basic framework of the proceeding. Boria holds the claimed Rule 11 lapse here is not structural.
  • “Red flags”: Observable signs suggesting the defendant does not understand (e.g., stating partial comprehension, contradictory answers, confusion, inability to follow questions, or counsel raising competency concerns).

V. Conclusion

United States v. Boria clarifies that, in the Second Circuit, a plea court confronted with a defendant’s recent medication use satisfies Rule 11 by making an on-the-record inquiry focused on present comprehension—particularly where the defendant confirms he is “clearheaded,” demonstrates understanding throughout the colloquy, and no competency concerns are raised. The decision also reinforces that on plain-error review, Rule 11 claims—medication-related or otherwise—ordinarily require a showing of prejudice under United States v. Dominguez Benitez, and cannot be reframed as “structural error” to bypass that requirement. In practical terms, Boria encourages targeted, comprehension-centered questioning and makes appellate relief difficult absent concrete evidence that medication actually impaired the plea decision.